In overweight, prediabetic schizophrenia patients taking second-generation antipsychotics, semaglutide (Ozempic) significantly improved insulin sensitivity, fasting glucose, and body weight.[1] In a study of 154 patients, semaglutide normalized blood sugar levels in 81% of those treated after 30 weeks.[1] Average weight loss was 9 kilograms compared to placebo and quality of life was improved.[1] Semaglutide treatment did not interfere with the treatment of schizophrenia and did not affect psychiatric symptoms.[1] The study is the largest of its kind, published in JAMA Psychiatry, and showed good tolerance of the drug in patients with schizophrenia.[1] The results suggest potential for reducing excess mortality in this group.[1]